Antinuclear Antibody Test Market Expected to Reach $5 Billion by 2031—Allied Market Research

According to a new report published by Allied Market Research, titled, “Antinuclear Antibody Test Market," The antinuclear antibody test market size was valued at $1.3 billion in 2021, and is estimated to reach $5 billion by 2031, growing at a CAGR of 15% from 2022 to 2031.

Antinuclear antibodies can be found in a person's blood serum using an antinuclear antibody test. Antinuclear antibody (ANA) testing is used to identify autoimmune illnesses that damage the tissues and organs of the body. These tests check the blood serum for antinuclear antibodies. Antibodies made by the human immune system defend the body from invaders such as viruses and bacteria. Antinuclear antibodies, on the other hand, attack the patient's own healthy cells and result in autoimmune illness.  Systemic lupus erythematosus, rheumatoid arthritis, scleroderma, and Sjogren's syndrome are just a few of the major health problems that can be brought on by autoimmune illnesses.

Rapidly increasing autoimmune disease incidences among people, across the globe, is  expected to be the main factor driving the global antinuclear autoimmune test market. Additionally, the majority of people have health insurance due to their rising health related awareness through government campaigns. This factor is predicted to accelerate the expansion of the market for antinuclear antibodies throughout the projected period. These factors are anticipated to propel the antinuclear antibody test market growth.

However, the market for antinuclear antibody tests may experience growth restrictions due to tight guidelines for medical device clearance and the need for large cash to purchase expensive equipment. Lack of qualified medical personnel will hinder market expansion.

The increase in people choosing medical insurance for financial security is anticipated to be a key driving factor for antinuclear antibody test market over the anticipated timeframe. Several governmental organizations are putting into action a number of initiatives to promote health insurance plans to give families financial security, which is anticipated to spur market expansion in the upcoming years. Additionally, it is predicted that the antinuclear antibody market will have plenty of growth opportunities in the predicted timeframe due to rising investments in the establishment and advancements of medical laboratories, particularly in developing countries where investments in healthcare infrastructure and test kits are rising.

The global antinuclear antibody test market share is segmented based on product, technique, application, end-use industry, and region. By product, the market is sub-segmented into reagents & assay kits, systems and software & services. By technique, ELISA, immunofluorescence assay and multiplex assay. By application, rheumatoid arthritis, systemic lupus erythematosus, sjogren’s syndrome, scleroderma and others. By end use, hospitals, clinical laboratories, physician office laboratories and others. By region, the market is analysed across North America, Europe, Asia-Pacific, and LAMEA.

The key players profiled in the antinuclear antibody test market report include Erba Diagnostics, Bio-Rad Laboratories, Inc., Trinity Biotech Plc., Thermo Fisher Scientific, Antibodies Incorporated, EUROIMMUN Medizinische Labordiagnostika AG, Immuno Concepts NA Ltd., Inova Diagnostics, Inc. and ZEUS Scientific, Inc.

The report offers a comprehensive analysis of the global antinuclear antibody test market trends by thoroughly studying different aspects of the market including major segments, market statistics, market dynamics, regional market outlook, investment opportunities, and top players working towards the growth of the market. The report also sheds light on the present scenario and upcoming trends & developments that are contributing to the growth of the market. Moreover, restraints and challenges that hold power to obstruct the market growth are also profiled in the report along with the Porter’s five forces analysis of the market to elucidate factors such as competitive landscape, bargaining power of buyers and suppliers, threats of new players, and emergence of substitutes in the market.

Impact of Covid-19 on the Global Antinuclear Antibody Test Industry

• The global antinuclear antibody testing market is anticipated to have a large uptick as a result of the pandemic. Due to the novel coronavirus outbreak, the majority of industrial sites have been closed, and many businesses have implemented work-from-home policies. However, healthcare institutions have taken numerous actions and are actively working on the creation of numerous vaccines and treating patients.
• The demand for antinuclear antibody test kits is anticipated to rise as more people conduct antinuclear antibody tests to diagnose autoimmune illnesses during the pandemic.

Key Findings of the Study

• Based on product, the reagents & assay kits sub-segment emerged as the global leader in 2021 and is anticipated to be the fastest growing sub-segment during the forecast period.
• Based on technique, the ELISA sub-segment emerged as the global leader in 2021 and is predicted to show the fastest growth in the upcoming years.
• Based on application, the rheumatoid arthritis sub-segment emerged as the global leader in 2021 and is predicted to show the fastest growth in the upcoming years.
• Based on end-use industry, the hospital sub-segment emerged as the global leader in 2021 and physician office laboratories sub-segment is predicted to show the fastest growth in the upcoming years.
• Based on region, the North America market registered the highest market share in 2021 and is projected to maintain the position during the forecast period.